Arena Pharmaceuticals rises on positive drug review
Shares of Arena Pharmaceuticals Inc. (Nasdaq:ARNA) are slightly above the flat line following news before the start of trading that an independent safety monitoring board gave a positive review of the company’s obesity drug. The Echocardiographic Data Safety Monitoring Board conducted a 12-month study that showed the drug Lorcaserin does not adversely affect the heart, the San Diego-based company said in a statement.
At 3:03 p.m. ET, shares had climbed $0.18, or 3%, to $6.49. For detailed price information and recent news stories about Arena Pharmaceuticals, click ARNA.
